Fulgent to Participate in Upcoming Conferences

FLGT 11.05.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-12
Name of Upcoming Event:UBS Global Healthcare Conference
Date of Upcoming Event:2024-12-04
Name of Upcoming Event:Piper Sandler 36th Annual Healthcare Conference
Full Press ReleaseSEC FilingsOur FLGT Tweets

About Gravity Analytica

Recent News

  • 12.04.2024 - Piper Sandler 36th Annual Healthcare Conference
  • 11.12.2024 - UBS Global Healthcare Conference
  • 11.08.2024 - Q3 2024 Fulgent Genetics Earnings Conference Call

Recent Filings

  • 01.08.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
  • 12.04.2024 - 4 Statement of changes in beneficial ownership of securities
  • 12.02.2024 - 144 Report of proposed sale of securities

EL MONTE, Calif.--(BUSINESS WIRE)--Nov. 5, 2024--Fulgent Genetics, Inc.(NASDAQ:FLGT) (“Fulgent,” or the “Company”), a technology-based company with a well-established laboratory services business and a therapeutic development business, today announced that members of its management team are scheduled to present at the following upcoming investor conferences:

  • UBS Global Healthcare ConferenceonTuesday, November 12that2:45 PM Pacific Time
  • Piper Sandler 36thAnnual Healthcare Conference onWednesday, December 4that11:30 AM Eastern Time

Live webcasts of the sessions will be available on the Investor Relations section of the Fulgent website atir.fulgentgenetics.com. Replay of the webcasts will be accessible at the same location beginning approximately one hour following the completion of the event.

About Fulgent

Fulgent is a technology-based company with a well-established laboratory services business and a therapeutic development business. Fulgent’s laboratory services business, which was formerly referred to as the clinical diagnostic business, includes technical laboratory services and professional interpretation of laboratory results by licensed physicians. Fulgent’s therapeutic development business is focused on developing drug candidates for treating a broad range of cancers using a novel nanoencapsulation and targeted therapy platform designed to improve the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The Company aims to transform from a genomic diagnostic business into a fully integrated precision medicine company.

View source version onbusinesswire.com:https://www.businesswire.com/news/home/20241105488393/en/

Investor Relations Contact:The Blueshirt GroupMelanie Solomon,melanie@blueshirtgroup.com

Source:Fulgent Genetics, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com